Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hinova Pharmaceuticals Buyback Yield % Related Terms
Hinova Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Hinova Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688302 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hinova Pharmaceuticals (SHSE:688302) has a Buyback Yield % of 0.00 as of Jul. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hinova Pharmaceuticals and its competitors. According to the industry distribution chart, Hinova Pharmaceuticals ranks #999999 out of 737 companies in the Biotechnology industry.
Is Hinova Pharmaceuticals' Buyback Yield % too high?
Hinova Pharmaceuticals' current Buyback Yield % is 0.00. Based on the distribution chart, Hinova Pharmaceuticals ranks #999999 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hinova Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #999999 out of 737 companies for Buyback Yield %. This places Hinova Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Hinova Pharmaceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Buyback Yield % is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
26GF Score
Get the complete analysis for SHSE:688302
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
